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a b s t r a c t
Twelve months dual antiplatelet therapy (DAPT) based on a combination of acetylsalicylic
acid and purine receptor P2Y12 inhibitor is a standard for all patients with acute coronary
syndrome (unstable angina pectoris, NSTEMI and STEMI). Previous sub-analysis of CURE and
ACUITY studies suggested that DAPT could bring beneﬁt even for patients treated by surgical
revascularization. Sub-analysis of PLATO trial conducted on 1261 patients, who underwent
surgical revascularization within 12 months, demonstrated a reduction of cardiovascular
and total mortality within a group of patients treated by ticagrelor and acetylsalicylic acid
compared to patients treated by clopidogrel and acetylsalicylic acid.
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According to current ESC guidelines for the management of
acute coronary syndrome in patients presenting with or
without ST-segment elevation, patients should undergo 12
months of dual antiplatelet therapy (DAPT) after the
myocardial infarction irrespective of whether they are
treated with percutaneous coronary intervention or conser-
vatively, with pharmacotherapy only [1,2]. Part of the
patients hospitalized due to acute coronary syndrome
(ACS) are treated with a coronary artery bypass graft (CABG)
in the acute stage, electively after discharge or later because
of progression of atherosclerosis or development of in-stent
restenosis. The number of patients treated with invasive
strategy at a higher age is growing along with the improved
care for patients with ACS. According to the Euroheart ACS
2001 survey of patients who underwent coronary angiogra-
phy for ACS suspicion, a total of 35.2% of men and 29.8% of
women aged 55–64 years, 38.8% of men and 34.1% of women
aged 65–74 years, and 46.6% of men and 40.1% of women
aged over 75 years had a three-vessel disease [3]. Table 1
illustrates the growing portion of invasively examined
patients with ACS between 1999 and 2008 (from 43% up to
85%); increasing proportion of patients were treated with
percutaneous coronary intervention (PCI) (from 21% up to
64%), while the number of patients treated with surgical
revascularization remains stable and moves around 11%.
The question remains whether a patient after ACS in whom
signiﬁcant and unstable atherosclerotic lesions were bridged
by CABG (arterial or venous) is stable and should be treated
similarly as a patient after surgical revascularization for the
stable form of coronary artery disease (CAD), or whether heTable 1 – Part of patients with acute coronary syndrome in
studies and registers who were examined invasively and
treated by percutaneous coronary intervention (PCI) and
surgical revascularization (CABG) between 1999 and 2008.
Coronary
angiography
PCI CABG
CURE (1999) [13] 43.7% 21.2% 16.5%
EHS-ACS I (2000) [3] 52.0% 25.4% 5.4%
GRACE registry (2000)
[14]
53% 28% 10%
EHS-ACS II (2004) [15] 62.9% 37.1% 7.4%
CZECH registry (2005)
[16]
85% 54% 12%
PLATO (STEMI and
NSTEMI) (2008) [17]
81.4% 64.1% 10.2%
PCI, percutaneous coronary intervention; CABG, coronary artery
bypass graft.still remains a patient after ACS with the presence of an
unstable atherosclerotic plaque and should be treated with
dual antiplatelet therapy for 12 months after the onset of ACS.
Antiplatelet therapy for patients post-CABG with a
stable form of CAD
According to ACCF/AHA guidelines, patients with a stable form
of CAD post-CABG revascularization should be treated with
acetylsalicylic acid (ASA) in a dose of 100–325 mg, which
should be administered perioperatively or as soon as the
patient's bleeding is stabilized – ideally 6 h after the surgery
and after 48 h at the latest. Clopidogrel is the alternative in the
case of ASA intolerance. This treatment lowers the risk of
venous graft closure. Warfarin did not turn out to be as
effective [4]. Two smaller recent studies demonstrated that
DAPT based on the combination of ASA with clopidogrel could
also be beneﬁcial for such stable patients after CABG. López
et al. reported in a group of 237 patients treated by CABG off-
pump that during 24-month follow-up, rehospitalization for
ACS decreased (10.9% vs. 3.7%, p = 0.035), and combined end-
point occurrence decreased as well (ACS, revascularization,
stroke and cardiovascular deaths; 18.8% vs. 8.3%; p = 0.02) with
dual antiplatelet therapy [5]. Gao at el. have demonstrated
lower risk of venous graft closure after three months of DAPT
with ASA plus clopidogrel compared to ASA itself (91.6% vs.
85.7%, p = 0.043) [6].
Dual antiplatelet treatment with clopidogrel
together with ASA after CABG in CURE and ACUITY
studies in ACS patients
Comparison of dual antiplatelet therapy with the combination
of ASA plus clopidogrel vs. ASA itself in ACS patients presented
without ST elevation was evaluated in the CURE study
(clopidogrel in unstable angina pectoris to prevent recurrent
ischemic events). Out of the total of 12,562 patients, 2072
underwent surgical revascularization during the course of the
study. The sub-analysis results were consistent with the
results of the entire study; the occurrence of combined
primary end-point (cardiovascular deaths, MI or stroke) was
lower in the group of patients treated with DAPT; however,
without reaching statistical signiﬁcance (14.5% vs. 16.2%;
RR = 0.98; 95% CI 0.71–1.11). The outcome was similar in
patients treated both in the early stage of ACS and during the
entire course of the study. The positive effect of DAPT was seen
especially during the period prior to surgical revascularization.
After surgery, the median of DAPT interruption (study
medication) was 10 days and DAPT was initiated again in
75.3% of the patients. The occurrence of cardiovascular events
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1.26). Patients with clopidogrel discontinuation <5 days before
surgery faced an insigniﬁcant rise in the risk of serious
bleeding [7].
The ACUITY study compared the effect of bivalirudin with
the combination of heparin plus glycoprotein IIb/IIIa inhibitors
in NSTEMI patients. Of the total number of patients, 1539
underwent surgical revascularization (11.1%). Patients pre-
treated with clopidogrel registered a lower incidence of
combined end-point within 30 days (deaths, MI or unplanned
revascularization – 12.7% vs. 17.3%; p = 0.01), manifested
especially by reduction in the number of myocardial infarc-
tions (8.8% vs. 14.5%; p = 0.01). Patients who discontinued
treatment with clopidogrel ≥5 days before surgery showed
better outcome. The incidence of serious bleeding associated
with surgery was comparable regardless of the clopidogrel pre-
treatment [8].
According to ESC guidelines for the management of
patients presenting without ST-segment elevation and accord-
ing to the Canadian Cardiovascular Society, dual antiplatelet
therapy may be maintained during surgery in the case of
particularly hazardous localization of coronary stenosis, e.g.
signiﬁcant impairment of left main with signiﬁcant stenosis of
the right coronary artery [2,9].
Comparison of dual antiplatelet therapy with
ticagrelor plus ASA compared to clopidogrel plus
ASA in ACS patients treated with surgical
revascularization in the PLATO study
The multicenter double-blind randomized clinical trial PLATO
compared the effect of the new direct reversible antagonist of
purine receptor P2Y12 ticagrelor with clopidogrel in a group of
18,624 ACS patients (unstable angina pectoris, NSTEMI and
STEMI). During the course of the entire study, 1899 patients
underwent surgical revascularization. According to the study
protocol, discontinuation of ticagrelor/placebo was recom-
mended 24–72 h before surgery and use of clopidogrel/placebo
ﬁve days before surgery. Sub-analysis of the effect of combined
DAPT was carried out in a group of 1261 patients, who were
treated with study medication <7 days before the surgery (632
patients received ticagrelor; 629 patients received clopidogrel).
The baseline characteristics of both patient groups were
comparable: the median age was 64 years; 21% of patients were
women; the previous PCI was carried out in 10.4% of the
patients and CABG in 1.5% of them. Fifty-seven percentage of
the patients underwent surgical revascularization during
initial hospitalization. Approximately 80% of the surgeries
were performed during the ﬁrst two months and 95% of them
did not require valve replacement. The number of peripheral
anastomoses was 1 or 2 in 31% of the patients, 3 or 4 in 60%,
and more than 5 in 8% of the patients. The interruption period
for study medication prior to surgery partly differed between
both groups with regard to the study protocol. Study
medication was re-started post-surgery in 63% of the patients.
The incidence of combined end-point (cardiovascular
deaths, MI or stroke) was lower in the ticagrelor group
compared to the clopidogrel group; however, the difference
was not statistically signiﬁcant (10.6% vs. 13.1%) and was inkeeping with the results of the entire study. This positive
result was especially caused by signiﬁcantly lower cardiovas-
cular mortality (4.1% vs. 7.9%; p = 0.009) and overall mortality
(4.7% vs. 9.7%; p = 0.002) (Fig. 1). No signiﬁcant difference in the
incidence of myocardial infarctions, non-cardiovascular
deaths or stroke was found (Table 2). The results of the
analysis, focusing on total mortality dependence on the
number of days from the last intake of study drug before
surgery, were very interesting (Fig. 2). Mortality was compara-
ble between both treated groups when the study medication
(ticagrelor or clopidogrel) was discontinued in the course of
24 h or 5 and more days before surgery. When the study drug
was discontinued 2, 3 or 4 days before surgery, much better
prognosis was reﬂected in the overall mortality in patients
treated with ticagrelor (3.4% vs. 15.5%; HR 0.21; 95% CI 0.10–
0.42; p < 0.01) as well as in cardiovascular mortality (3.1% vs.
11.8%; HR 0.25; 95% CI 0.12–0.53; p < 0.05) [10].
Bleeding events in CABG-treated patients in the
PLATO study
Nearly all the bleeding events occurred within 24 h after
surgery. Bleeding was evaluated according to several deﬁni-
tions and criteria; however, the results were similar in both
treatment groups, according to the PLATO study deﬁnitions –
major CABG-related bleeding: 81.3% vs. 80.1%; life-threaten-
ing/fatal CABG-related bleeds: 42.6% vs. 43.7%; bleeding
according to TIMI major criteria: 57.6% vs. 59.3%; bleeding
according to TIMI minor criteria: 21.6% vs. 21.2%; according to
GUSTO study severe bleeding criteria: 10.6% vs. 12.2%. There
was no difference in chest tube drainage and bleeding
evaluated according to the CABG-related hemoglobin drop
>50 g/l in both groups. Fig. 3 indicates lower impact of
perioperative bleeding on hemoglobin concentration when
the interval from the last intake of the study drug was at least
ﬁve days [10].
Factors affecting lower post-CABG mortality in the
group of patients treated with ticagrelor compared
to clopidogrel
An interesting sub-analysis was published in 2012 focusing on
the causes of deaths of all patients treated with surgical
revascularization (29 deaths out of 632 patients receiving
ticagrelor and 58 deaths out of 629 patients in the group
receiving clopidogrel). In addition to reviewing the primary
cause of death, bleeding or infections that could have
contributed to the death were evaluated by independent
experts. As has already been stated above, a signiﬁcantly lower
number of cardiovascular deaths were reported in the group of
patients treated with ticagrelor; however, none of the
subcategories (myocardial infarction, heart failure, sudden
death/arrhythmia, stroke, pulmonary embolism and bleeding)
reached statistical signiﬁcance. As a primary cause of death,
infectious diseases appeared non-signiﬁcantly more frequent-
ly in the clopidogrel group.
However, when evaluating all deaths to which bleeding
contributed or of which it was the primary cause, the number
Fig. 1 – Cumulative risk of total mortality (A) and cardiovascular mortality (B) after CABG in the ticagrelor group and clopidogrel
group.
Source: Held et al. [10], published with the permission.
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with the ticagrelor group (4.6% vs. 1.4%; p < 0.01). Similarly, the
number of deaths in the clopidogrel group was higher when
evaluating infection as the primary cause of death or as
contributing to death (2.9% vs. 1.0%; p < 0.05) (Fig. 4). This
mechanism has not been fully clariﬁed [11].Dual antiplatelet therapy in the Triton-TIMI 38
study based on combining prasugrel and ASA
Information about the possible beneﬁt of a new antiplatelet
agent prasugrel compared to clopidogrel in ACS patients
Table 2 – Incidence of selected end-points after a coronary artery bypass graft in the PLATO study population.
Ticagrelor
(n = 629)
Clopidogrel
(n = 629)
HR (95% CI) p
Primary end-point
(CV deaths/MI/stroke)
66 (10.6%) 79 (13.1%) 0.84 (0.60–1.16) 0.286
MI 37 (6.0%) 35 (5.7%) 1.06 (0.66–1.68) 0.819
Total mortality 29 (4.7%) 58 (9.7%) 0.49 (0.32–0.77) 0.002
CV deaths 25 (4.1%) 47 (7.9%) 0.52 (0.32–0.85) 0.009
Non-cardiovascular
deaths
4 (0.7%) 12 (2.0%) 0.35 (0.11–1.11) 0.075
Stroke 13 (2.1%) 11 (2.1%) 1.17 (0.53–2.62) 0.697
Source: Held et al. [10], published with the permission.
CV deaths, cardiovascular deaths; MI, myocardial infarction.
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TIMI 38 study, which randomized ACS patients (STEMI,
NSTEMI and unstable AP) for treatment using ASA combined
with either prasugrel 10 mg or clopidogrel 75 mg. A total of
13,608 patients were randomized for invasive PCI treatment.
Subsequently, 448 patients underwent surgical revasculariza-
tion during the course of more than 12-month monitoring.
Sub-analysis included 346 patients who received at least one
dose of the study antiplatelet therapy. Most surgeries were
elective with more than a 90-day interval from the ACS.
Discontinuation of antiplatelet drugs was recommended
seven days prior to surgery. It is interesting to note that a
total of four patients in the group treated with clopidogrel
experienced a myocardial infarction when medication was
discontinued. A signiﬁcantly higher chest tube blood lossFig. 2 – Risk of death depending on the period from the last inta
Source: Held et al. [10], published with the permission.(655  580 ml vs. 503  378 ml; p = 0.05) was observed with
prasugrel compared with clopidogrel, without signiﬁcant
differences in red blood cell transfusion (2.1 U vs. 1.7 U;
p = 0.442) or the total donor exposure (4.4 U vs 3.0 U;
p = 0.463). The incidence of platelet transfusion was signiﬁ-
cantly higher in the prasugrel group compared with the
clopidogrel group (17.9% vs. 9.8%; p = 0.03). There was a
trend toward a higher incidence of surgical re-exploration
for bleeding in the prasugrel group (11 patients vs. 4
patients). DAPT was re-started after surgery in 72% of the
patients (open-label or study medication). All-cause mortal-
ity was signiﬁcantly reduced with prasugrel compared with
clopidogrel (2.31% vs. 8.67%, OR: 0.26 (95% CI: 0.08–0.85);
p = 0.025), as well as cardiovascular mortality (1.73% vs.
6.94%, OR 0.25 (95% CI: 0.08–0.98); p =0.047) [12]. With regardke of study medication prior to CABG.
Fig. 3 – Proportion of patients with a decrease in hemoglobin ≥50 g/l by days from the last intake of the study drug.
Source: Held et al. [10], published with the permission.
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revascularization, there is no sufﬁcient amount of data, and
according to guidelines, using prasugrel in ACS patients
undergoing CABG is not recommended.
Risk stratiﬁcation of patients with NSTEMI and
coronary angiography timing
It is clear from the preceding results that DAPT may increase
the risk of bleeding complications when not discontinued well
in advance of surgery in line with guidelines. High-risk
patients with ACS presenting without ST-segment elevation,
who should undergo invasive examination within 2 h accord-
ing to risk stratiﬁcation and who have increased risk of acute
surgery, should be treated with dual antiplatelet therapy only
according to the angiography result. No data is available for
patients undergoing coronary angiography within 24 h and
initiation of dual antiplatelet therapy must be decided on an
individual basis. This highlights the importance of risk
stratiﬁcation of patients with ACS without ST-segment
elevation. According to ESC guidelines, acute coronary
angiography should be performed within 2 h for patients with
refractory angina pectoris, heart failure, malignant arrhythmia
or right bundle branch block. It should be carried out within
24 h in the group of patients with a GRACE score value >140
and at least one other risk factor (positive troponin, dynamic
changes of ST segment or T wave, diabetes mellitus, renal
insufﬁciency – eGFR < 60 ml/min/1.73 m2, EF < 40%, post-
infarction AP, recent PCI or previous CABG), while acute
angiography should be carried out within 72 h in patients with
a GRACE score < 140 and one of the above-mentioned risk
factors [2].Current DAPT strategy in patients prior to and after
surgical revascularization for acute coronary
syndrome
ACS patients beneﬁt from DAPT if they are treated with
surgical revascularization over the course of 12 months since
the initial ischemic episode. If the patient is stable and surgical
revascularization is not carried out immediately after the
coronary event, he should be treated with DAPT based on the
combination of ticagrelor and ASA until the surgery. Clopido-
grel is the alternative in the event of intolerance or the
impossibility of administering ticagrelor. Dual antiplatelet
therapy should be discontinued prior to surgical revasculari-
zation: clopidogrel and ticagrelor 5 days and prasugrel 7 days
before the surgery (according to ESC guidelines). In urgent
cases when there is a high risk of bleeding, discontinuation of
clopidogrel or ticagrelor even for 24 h before surgery may lower
the risk of bleeding. Surgical revascularization with main-
tained DAPT is to be considered with the high-risk coronary
ﬁnding. Acetylsalicylic acid should be administered periopera-
tively; in the case of ASA discontinuation, administration
should be initiated early – 6–48 h after the surgery at the latest
unless anticoagulation treatment is indicated (e.g. due to valve
replacement or atrial ﬁbrillation). DAPT should be restarted
after stabilizing the patient and after management of any
possible bleeding complications. DAPT based on ASA and
ticagrelor (clopidogrel could be a less suitable alternative)
should last 12 months since ACS (Table 3).
Finally, it must be noted that although the above review
should bring the maximum currently available information
about DAPT in ACS patients undergoing CABG, the individual
net clinical beneﬁt and bleeding risks associated with DAPT
Table 3 – Main principles of DAPT in patients with acute
coronary syndrome treated by surgical revascularization.
ASA should be administered perioperatively; in the case of ASA
discontinuation, administration should be initiated early – 6–48
h after the surgery at the latest.
DAPT based on the combination of ticagrelor plus ASA
(alternative clopidogrel plus ASA) in patients with ACS treated
by CABG should last 12 months since ACS.
DAPT should be discontinued prior to surgical
revascularization: clopidogrel and ticagrelor 5 days and
prasugrel 7 days.
Surgical revascularization with maintained DAPT is to be
considered with the high-risk coronary ﬁnding.
DAPT should be restarted after stabilizing the patient and after
management of any possible bleeding complications.
The individual net clinical beneﬁt and bleeding risks associated
with DAPT must always be considered and should lead to
individual timing of DAPT in the period around CABG.
Fig. 4 – Kaplan–Meier estimates of time to death depending
on bleeding (A) and infection (B) as a direct cause or
contributing factor.
Source: Varenhorst et al. [11], published with the
permission.
c o r e t v a s a 5 6 ( 2 0 1 4 ) e 2 4 6 – e 2 5 3e252must always be considered. Efforts to minimize the possible
complications for the patient should lead to individual timing
of DAPT in the period around CABG.
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